✦ LIBER ✦

The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus

✍ Scribed by Roy, Thomas M.; Broadstone, Vasti L.; Peterson, Hugh R.; Snider, Harvy L.; Cyrus, Jahangir; Fell, Ronald; Rothchild, Armand H.; Samols, Ellis; Pfeifer, Michael A.

Book ID: 122517798
Publisher: Elsevier Science
Year: 1990
Tongue: English
Weight: 657 KB
Volume: 10
Category: Article
ISSN: 0168-8227
DOI: 10.1016/0168-8227(90)90086-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of 24 weeks of treatment with epa

Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus

✍ Kenzo Uchida; Toshikazu Kigoshi; Shigeru Nakano; Takashi Ishii; Mitsutaka Kitaza 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 475 KB

Long-term effect of an aldose reductase

Long-term effect of an aldose reductase inhibitor on development of incipient nephropathy in type 2 diabetes mellitus

✍ K Iso; H Tada; K Kuboki; Y Tojho; K Mogami; T Inokuchi 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 150 KB

Effects of an aldose reductase inhibitor

Effects of an aldose reductase inhibitor on gastroenteropathy in streptozotocin-diabetic rats

✍ M Oya; M Hosokawa; H Tsukada; K Fukuda; H Nakamura; K Tsukiyama; K Nagashima; S 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 247 KB

The effect of an aldose reductase inhibi

The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats

✍ Iori Itagaki; Kiyoshi Shimizu; Yoshihisa Kamanaka; Kazuhiko Ebata; Ryuichi Kikka 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 782 KB

Effect of tolrestat, an aldose reductase

Effect of tolrestat, an aldose reductase inhibitor, on neutrophil respiratory burst activity in diabetic patients

✍ Sung-Hee Ihm; Hyung Joon Yoo; Sung Woo Park; Chan Jeoung Park 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 477 KB

Long-Term Clinical Effects of Epalrestat

Long-Term Clinical Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral Neuropathy: The 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial

✍ Hotta, N.; Akanuma, Y.; Kawamori, R.; Matsuoka, K.; Oka, Y.; Shichiri, M.; Toyot 📂 Article 📅 2006 🏛 American Diabetes Association 🌐 English ⚖ 225 KB